Jaguar Health Reports 2021 Third Quarter Financial Results Mytesi prescription volume increased 7.6% in Q3 2021 over Q2 2021 Third quarter 2021 Mytesi net and gross sales were approximately $0.6 million and approximately

Reports 2021 Third Quarter Financial Results

prescription volume increased 7.6% in Q3 2021 over Q2 2021

2021 Mytesi net and gross sales were approximately $0.6 million and approximately $3.2 million

to complete transition to selling Mytesi through closed specialty pharmacy network by end of 2021 as part of Company's market access

2021 milestones: Presentation of Phase 2 HALT-D study results at San Antonio Breast Cancer Symposium & launch of Canalevia -CA1

for chemotherapy-induced diarrhea in dogs

Jaguar to host investor webcast today (Wednesday, November 17th) at 8:30 a.m. Eastern regarding third quarter 2021

financials & business updates; Click here to register for webcast

SAN FRANCISCO, CA / November 17,

2021 / Jaguar Health, Inc. (NASDAQ: JAGX) ("Jaguar" or the "Company") today reported consolidated third

quarter 2021 financial results.

Mytesi (crofelemer) prescription volume,

the metric the Company believes to be the best indicator of patient demand, increased 7.6% in the third quarter of 2021 over the second

quarter of 2021, and new Mytesi prescriptions increased 9.0% during the same period. Mytesi total prescription volume remained the same

in the third quarter of 2021 over the third quarter of 2020 and new Mytesi prescriptions increased by 10.5% during the same period. Prescription

volume differs from invoiced sales volume.

As previously announced, the Company

is in the process of transitioning a substantial amount of Mytesi volume to a closed network of specialty pharmacies (rather than to

wholesalers that resell the product to retail pharmacies) by the end of 2021. This transition results in an underrepresentation of Mytesi

utilization, as revenue related to wholesaler inventory has already been recognized by Jaguar, and that inventory has now been brought

down. A key component of the Company's market access strategy, this initiative is intended to help remove access barriers for patients

receiving Mytesi, and includes services such as a higher level of support for prior authorizations, appeals, adherence counseling, and

home delivery options. While patients often visit retail pharmacies for short-term or uncomplicated medical needs, specialty pharmacies

focus on serving patients with complex and chronic medical conditions like HIV. The transition to a closed network of specialty pharmacies

is expected to result in a meaningful reduction in Mytesi distribution costs and prepares the Company's U.S. commercial distribution

network for future indication expansion of crofelemer to other populations of patients with complex medical needs.

Clinical & Product Development

2021 Third Quarter Company Financial

Note Regarding Use of Non-GAAP Measures

The Company supplements its condensed

consolidated financial statements presented on a GAAP basis by providing gross sales, non-GAAP EBITDA, and non-GAAP recurring EBITDA,

which are considered non-GAAP under applicable SEC rules. Jaguar believes that the disclosure items of these non-GAAP measures provide

investors with additional information that reflets the basis upon which Company management assesses and operates the business. These

non-GAAP financial measures are not in accordance with GAAP and should not be viewed in isolation or as substitutes for GAAP net sales

and GAAP net loss and are not substitutes for, or superior to, measures of financial performance in conformity with GAAP.

Gross sales percentages issued by the

Company are based on gross sales figures that represent Mytesi orders placed by wholesalers with Jaguar's third-party logistics

warehouse, less allowances for rebates, chargebacks, and discounts, which generate the cash flows for Napo Pharmaceuticals, Inc. ("Napo"),

Jaguar's wholly owned subsidiary. Gross sales are used internally by management as an indicator of and to monitor operating performance,

including sales performance of Mytesi, salesperson performance, and product growth or declines. The Company believes that the presentation

of gross sales provides a closer to real-time useful measure of our operating performance. Gross sales are not a measure that is recognized

under accounting principles generally accepted in the United States of America ("GAAP") and should not be considered as an

alternative to net sales, which is determined in accordance with GAAP, and should not be used alone as an indicator of operating performance

in place of net sales. Additionally, gross sales may not be comparable to similarly titled measures used by other companies, as gross

sales have been defined by the Company's internal reporting practices. In addition, gross sales may not be realized in the form

of cash receipts as promotional payments and allowances may be deducted from payments received from certain customers. Mytesi gross sales

are reduced by Medicare, ADAP 340B chargebacks, returns, and wholesale distribution fees based on historical trends to determine net

The Company defines non-GAAP EBITDA

as net loss before interest expense and other expense, depreciation of property and equipment, amortization of intangible assets,

share-based compensation expense and provision for or benefit from income taxes. The Company defines non-GAAP Recurring EBITDA as

non-GAAP EBITDA adjusted for certain non-recurring revenues and expenses. Company management believes that non-GAAP EBITDA and

non-GAAP Recurring EBITDA are meaningful indicators of Jaguar's performance and provide useful information to investors

regarding the Company's results of operations and financial condition.

Participation Instructions for Today's

When: Wednesday, November 17, 2021,

at 8:30 AM Eastern Time

Participant Registration & Access

Replay Instructions for Webcast

Replay of the webcast on the investor

relations section of Jaguar's website: (click here)

About Jaguar Health, Inc., Napo Pharmaceuticals,

Inc. & Napo EU S.p.A.

Jaguar Health, Inc. is a commercial

stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for

GI distress, specifically chronic, debilitating diarrhea. Our wholly owned subsidiary, Napo Pharmaceuticals, Inc., focuses on developing

and commercializing proprietary plant-based human gastrointestinal pharmaceuticals from plants harvested responsibly from rainforest

areas. Our Mytesi (crofelemer) product is approved by the U.S. FDA for the symptomatic relief of noninfectious diarrhea

in adults with HIV/AIDS on antiretroviral therapy and the only oral plant-based prescription medicine approved under FDA Botanical Guidance.

Crofelemer is the subject of the OnTarget study, an ongoing pivotal Phase 3 clinical trial for prophylaxis of diarrhea in adult cancer

patients receiving targeted therapy. Napo EU S.p.A., the majority owned Italian subsidiary of Napo Pharmaceuticals, focuses on expanding

crofelemer access in Europe.

For more information about Jaguar, please

visit https://jaguar.health. For more information about Napo Pharmaceuticals, visit www.napopharma.com. For more information about Napo

EU, visit www.napoeu.com.

Mytesi (crofelemer) is an antidiarrheal

indicated for the symptomatic relief of noninfectious diarrhea in adult patients with HIV/AIDS on antiretroviral therapy (ART). Mytesi

is not indicated for the treatment of infectious diarrhea. Rule out infectious etiologies of diarrhea before starting Mytesi. If infectious

etiologies are not considered, there is a risk that patients with infectious etiologies will not receive the appropriate therapy and

their disease may worsen. In clinical studies, the most common adverse reactions occurring at a rate greater than placebo were upper

respiratory tract infection (5.7%), bronchitis (3.9%), cough (3.5%), flatulence (3.1%), and increased bilirubin (3.1%).

See full Prescribing Information at

Mytesi.com. Crofelemer, the active ingredient in Mytesi, is a botanical (plant-based) drug extracted and purified from the red bark sap

of the medicinal Croton lechleri tree in the Amazon rainforest. Napo has established a sustainable harvesting program for crofelemer

to ensure a high degree of quality and ecological integrity.

Forward-Looking Statements

Certain statements in this press

release constitute "forward-looking statements." These include statements regarding the Company's expectation that

essentially a full transition to Mytesi prescriptions being dispensed through specialty pharmacies will be complete by the end of

2021, the expectation that results of the Phase 2 HALT-D study will be presented at the San Antonio Breast Cancer Symposium in

December 2021, the Company's expectation that the conditional approval and launch of Canalevia -CA1 for CID

in dogs will take place in late-December 2021, the expectation that a final decision about ODD for crofelemer for SBS in the EU may

occur within the next 30 days, the expectation that Jaguar will host an investor webcast on November 17, 2021, the Company's

expectation that the transition to a closed network of specialty pharmacies will result in a meaningful reduction in Mytesi

distribution costs, and the Company's plans to grow the Napo EU team in Italy. In some cases, you can identify forward-looking

statements by terms such as "may," "will," "should," "expect," "plan,"

"aim," "anticipate," "could," "intend," "target," "project,"

"contemplate," "believe," "estimate," "predict," "potential" or